29 C
Vientiane
Tuesday, April 29, 2025
spot_img
Home Blog Page 761

Fiji Airways Unveils Huge Sale to Fiji, Australia, New Zealand and Beyond!

NADI, Fiji, Jan. 17, 2025 /PRNewswire/ — Fiji Airways, Fiji’s national airline, has launched incredible flight deals for Canadian travelers looking to escape the winter chills for tropical thrills.

Until February 7, 2025, Fiji Airways is offering significant savings on round-trip airfares to some of the world’s most sought-after destinations, including the pristine beaches of Fiji, the Great Barrier Reef in Cairns, the iconic landmarks of Sydney, the vibrant streets of Auckland and beyond.

Available on select travel dates, travelers can Fly from Vancouver, Canada to:

  • Fiji (Nadi) from just CAD $999, on a Roundtrip VALUE fare
  • Australia from CAD $1339, on a Roundtrip VALUE fare
  • New Zealand from CAD $1339, on a Roundtrip VALUE fare
  • Tonga & Western Samoa from CAD $1599, on a Return VALUE fare

All economy value fares include one checked bag of up to 30kg, a carry-on bag of up to 7kg, complimentary meals, beverages, and in-flight entertainment, with additional fare options available for those seeking added perks and convenience.

The sale ends February 7, 2025 and is valid for select travel dates across 2025, with limited seats available. Terms and conditions apply.

Travelers can book now on fijiairways.com or through a local travel agent to experience Fiji Airways’ award-winning hospitality.

This time of year is the perfect opportunity to take advantage of discounted airfares and plan your travel adventures for the year ahead. We’re excited to offer these incredible deals, making it easier than ever for Canadians to discover the warmth and beauty of Fiji or explore vibrant destinations like Australia and New Zealand” said Fiji Airways CEO and Managing Director Andre Viljoen.

Fiji Airways connects directly to 26 international destinations from its hub in Nadi, Fiji and offers seamless one-stop connections for Canadians to popular cities including but not limited to:

  • Australia: Sydney, Melbourne, Brisbane, Adelaide, Canberra and Cairns from 10th April 2025
  • New Zealand: Auckland, Wellington, Christchurch
  • The South Pacific: Tonga, Western Samoa

About Fiji Airways:

Fiji Airways has been named SKYTRAX Best Airline in Australia and the Pacific 2024 for two consecutive years and is ranked 14th in SKYTRAX Global Top 100 Airlines.  The airline was also awarded Best Airline Staff, Best Cabin Crew, Best Economy Class and Best Business Class Onboard Catering in Australia and the Pacific at the 2024 SKYTRAX awards. Fiji Airways has also received the esteemed Five Star Major Airline Award at the 2024 APEX Official Airline Ratings™, an award the airline has been recognised with for three consecutive years.

Founded in 1951, the Fiji Airways airline group comprises Fiji Airways, Fiji’s international airline, and its wholly-owned domestic and regional subsidiary, Fiji Link. From its hubs at Nadi and Suva International Airports, Fiji Airways and Fiji Link serve 108 destinations in over 15 countries (including code-share). Destinations include Fiji, Australia, New Zealand, the US, Canada, the UK, Hong Kong (SAR China), Singapore, India, Japan, China, Samoa, Tonga, Tuvalu, Kiribati, Vanuatu, Solomon Islands and New Caledonia. The Fiji Airways Group brings in 70 percent of all visitors who fly to Fiji, employs over 2000 employees, and earns revenues of over FJD$1.7 billion (USD $770m) in 2023. Fiji Airways rebranded from Air Pacific in June 2013. Visit www.fijiairways.com for more information.

Kia India Begins Production of Syros SUV

  • Kia Syros SUV records 10,258 pre-orders, continuing impressive momentum following world premiere in December 2024
  • New family-focused SUV specifically designed for customers in India
  • Groundbreaking design, cutting-edge technology, advanced safety, sophisticated materials and exceptional space transform SUV sector
  • Kia Syros sales will begin on February 1; customer deliveries to follow shortly after

ANANTAPUR, India, Jan. 17, 2025 /PRNewswire/ — Kia India has commenced mass production of the Kia Syros, a versatile SUV specifically designed to meet the needs of customers in India. Officially unveiled in December 2024, the Syros SUV sets new standards in design, technology, and space.

Kia India Begins Production of Syros SUV
Kia India Begins Production of Syros SUV

Kia held a milestone ceremony at its plant in Anantapur, Andhra Pradesh, India, to mark the beginning of Syros production, continuing the significant momentum built by the vehicle’s world premiere in December 2024. The event was attended by senior Kia executives and employees, including Ho Sung Song, President and CEO of Kia Corporation, and Gwanggu Lee, Managing Director of Kia India.

The Kia Syros recorded 10,258 pre-sales, signaling the significant market potential for the Syros in India.

The five-seat Syros SUV has been designed and engineered following in-depth analysis of local market trends to ensure that it precisely meets the needs of Indian consumers.

“We’re delighted with the interest our customers in India have already shown in the new Kia Syros SUV,” said Ho Sung Song, President and CEO of Kia. “This is a positive sign ahead of the Syros’s market introduction in India and a testament to Kia’s customer-centric focus, delivering vehicles that provide value to our customers through the innovative features and services on offer.”

The advanced design, practicality and connectivity features offered on the Syros have been key drivers in the initial market interest Kia has already received.

Kia’s ‘Opposites United’ design philosophy effortlessly blends bold lines with functional versatility to create a unique, family-focused SUV with a striking, futuristic and sophisticated aesthetic.

Inside, the Syros’s functionality and elegant design maximize interior space. The Syros also introduces innovative technology to set new standards in its class, meeting the demands of Indian consumers who are increasingly seeking the latest trends, features and sophisticated materials.

The model introduces first-in-segment rear sliding, reclining and ventilated seats, as well as cutting-edge connectivity with more than 80 connected features. The Syros also offers a dual-pane panoramic sunroof, a Harman Kardon Premium 8 Speaker Sound System, and first-in-segment Over-the-Air (OTA) software update capability.

Safety is further enhanced through Level 2 Advanced Driver Assistance Systems (ADAS) with 16 autonomous safety features, including Forward Collision Avoidance Assist, Lane Keep Assist, a 360 Degree Camera with Blind View Monitor and Smart Cruise Control with Stop & Go. This is complemented by a comprehensive suite of 20 standard hi-safety features, such as Electronic Stability Control, Hill Start Assist control, six airbags, Vehicle Stability Management, and Electric Parking Brake with Auto Hold, ensuring maximum protection for both driver and passengers.

Kia Syros sales will officially begin in India from February 1, with first customer deliveries to follow shortly after. Kia plans to expand the Syros’s availability to markets in the Asia-Pacific, Latin America, and Middle East regions.

This new SUV is the latest locally tailored step in Kia’s global commitment to provide its customers with sustainable mobility solutions that offer industry-leading technology and services.

For more information on the new Kia Syros, including powertrain, design and further product features, click here for the full World Premiere press release.

About Kia India
In April 2017, Kia India signed a memorandum of understanding (MOU) with the State Government of Andhra Pradesh, India, to build a new manufacturing facility at Anantapur District. Kia commenced mass production in August 2019 and has an installed annual production capacity of 300,000 units. In April 2021, Kia India reimagined itself in line with its new brand identity, “Movement that Inspires” aimed at offering customers meaningful experiences backed by innovative products and services. Under the new brand identity, Kia has set out to find ways to achieve new benchmarks and inspire consumers to be more and do more. Till date, Kia India has launched five vehicles for the Indian market – the Seltos, the Carnival, the Sonet, the Carens, and the EV6. Kia India has completed almost 1.6 million vehicle dispatches from its Anantapur plant, including over 1.2 million domestic sales and over 3.67 lakh exports. With more than 4.5 lakh connected cars on Indian roads, it is among the connected Car leaders in the country. The brand has a widespread network of 700 touchpoints across 300 cities and is focused on strengthening its footprints across the country.

Visit – Kia Showroom 

Kia Corporation – about us
Kia (www.kia.com) is a global mobility brand with a vision to create sustainable mobility solutions for consumers, communities, and societies around the world. Since 1944 Kia has been providing mobility solutions. With 52,000 employees worldwide, a presence in more than 190 markets, and manufacturing facilities in six countries, the company today sells around three million vehicles a year. Kia is spearheading the popularization of electrified and battery electric vehicles and developing a growing range of mobility services, encouraging millions of people around the world to explore the best ways of getting around. The company’s brand slogan – ‘Movement that inspires’ – reflects Kia’s commitment to inspire consumers through its products and services.

For more information, visit the Kia Global Media Center at www.kianewscenter.com

 

LOTTE BIOLOGICS to Present at the 2025 J.P. Morgan Healthcare Conference

  • New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on “Advancing as a Global CDMO Leader”
  • Unveiling of Next-Generation ADC Platform ‘SoluFlex Link’: Enabling High-Potency, High-Yield ADC Development and Manufacturing
  • Incheon Songdo Bio Campus Plant 1 Under Construction, Targeting Commercial Production by 2027

SEOUL, South Korea, Jan. 17, 2025 /PRNewswire/ — LOTTE BIOLOGICS (CEO James Park) announced on January 16 that it had presented at the “Asia-Pacific (APAC)” track of the J.P. Morgan Healthcare Conference (JPMHC).

The 2025 J.P. Morgan Healthcare Conference, now in its 43rd year, is the largest event in the pharmaceutical and biotechnology industries. Held in San Francisco, it runs from January 13 to 16 and brings together global pharmaceutical companies, biotech ventures, and healthcare investment professionals to discuss research and development (R&D), investment opportunities, and partnerships.

In his presentation, CEO James Park highlighted the successful transformation of the Syracuse Bio Campus in New York into a CDMO facility and outlined the vision for the Songdo Bio Campus. Notably, he unveiled the company’s innovative proprietary ADC platform, SoluFlex Link, and announced plans to collaborate with drug product partners in North America to provide a comprehensive one-stop ADC service. Through these initiatives, he expressed LOTTE BIOLOGICS’ ambition to accelerate its growth in the global CDMO market.

SoluFlex Link is a proprietary ADC platform featuring a linker technology jointly developed by LOTTE BIOLOGICS and Kanaph Therapeutics, a biotech venture specializing in drug-conjugation technology.

SoluFlex Link overcomes the major challenge of instability in antibody-drug conjugate (ADC) therapeutics. Its flexible design supports compatibility with a wide range of antibodies and payloads, empowering ADC developers to innovate with diverse applications. Additionally, the platform is engineered to boost both production efficiency and therapeutic performance, positioning it as an ideal solution for next-generation ADC development and manufacturing.

Meanwhile, LOTTE BIOLOGICS’ Syracuse Bio Campus received a flawless quality evaluation last year, with no findings reported during inspections by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) and a routine audit by the U.S. Food and Drug Administration (FDA). CEO Park emphasized, “Even after the acquisition of the facility, we have maintained a high-quality production system, demonstrating our capabilities as a global CDMO company.”

He explained that this served as an opportunity to demonstrate that LOTTE BIOLOGICS has established a global quality management system capable of producing high-quality biopharmaceuticals in compliance with international standards.

In addition, construction of Plant 1 at the Songdo Bio Campus began in March last year, with a total investment of $1 billion. The facility is currently under active development, aiming to commence full-scale commercial production by 2027.

CEO Park stated, “The Songdo Bio Campus Plant 1, scheduled for completion this year, will be a flexible, large-scale production facility equipped with an optimized operational system. By incorporating automated production processes and advanced manufacturing technologies, and leveraging the geographical advantages of Songdo and New York, we will maximize operational efficiency. We are committed to becoming a global company that not only ensures customer satisfaction but also achieves competitive quality standards.”

Yu-Yeol Shin, Vice President and Head of Global Strategy at LOTTE BIOLOGICS, also attended the J.P. Morgan Conference for the first time since his appointment in late 2023. During the event, he participated in presentation sessions by companies such as Roche, Johnson & Johnson (J&J), and BMS to gain insights into pharmaceutical and biotechnology trends. Additionally, alongside CEO James Park, he actively engaged in business and partnership meetings with global pharmaceutical companies and potential clients, demonstrating a strong commitment to advancing LOTTE Group’s new biopharmaceutical business.

[Appendix: Summary of CEO James Park’s 2025 JPMHC Presentation]

  • Unveiling of the Next-Generation ADC Platform ‘SoluFlex Link’

In this presentation, CEO James Park unveiled LOTTE BIOLOGICS’ innovative ADC platform, SoluFlex Link, for the first time. SoluFlex Link is an ADC platform with the flexibility to be applied to most linkers and payloads used in ADCs, meeting the diverse needs of various clients.

CEO Park explained, “SoluFlex Link enhances the hydrophilicity of ADCs, demonstrating improved efficacy in terms of in vivo performance, stability, productivity, and pharmacokinetics. This makes it an effective and accelerated drug development solution for next-generation ADC development and manufacturing.”

He added, “A key advantage is that the Syracuse Bio Campus in New York can meet a wide range of client needs, from clinical development-scale production to large-scale commercial manufacturing.”

  • Establishing ADC End-to-End Service Partnerships

Additionally, it was emphasized that with the operation of the ADC conjugation facility in Syracuse, the launch of the SoluFlex Link platform, and partnerships for ADC drug product (DP) manufacturing, the company is now capable of providing end-to-end ADC services within North America.

At the Syracuse Bio Campus, antibodies and ADC drug substances (DS) will be produced and supplied to drug product (DP) CDMO partners located on the East and West Coasts of the United States. The collaboration is structured to handle all stages of ADC drug development and production, from process development to manufacturing.

  • Accelerating Construction of the Songdo Bio Campus with Targeted Commercial Production by 2027

LOTTE BIOLOGICS also shared updates on the progress of the large-scale biopharmaceutical production facility under construction at the Songdo Bio Campus. CEO Park stated, “The construction of Plant 1 is progressing smoothly, with the goal of commencing full-scale commercial production in 2027.”

In addition, the “TiterFlex Quad Bioreactor System,” designed to meet the demand for high-titer drug production, is currently undergoing Factory Acceptance Testing (FAT). Alongside this, automation technologies are being implemented to enhance efficiency from raw material handling to production, with a strong focus on optimizing operational efficiency.

James Park, CEO, presenting at 2025 JPMHC
James Park, CEO, presenting at 2025 JPMHC

About LOTTE BIOLOGICS

Headquartered in Seoul, South Korea, LOTTE BIOLOGICS was founded in 2022 with a mission to deliver therapies that contribute to a healthier world.

At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. The facility offers a total production capacity of 40,000L, supported by eight 5,000L stainless steel bioreactors. Additionally, the campus includes extensive analytical QC testing laboratories and warehouse facilities that have received approval from over 62 regulatory agencies worldwide. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) conjugation services, expected to be fully operational by early 2025. With over $80 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation.

Looking ahead to 2030, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2027, each facility will feature eight 15,000L stainless steel bioreactors for large-scale commercial production, along with multiple 2,000L single-use bioreactors to meet clinical production needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity.

More information about LOTTE BIOLOGICS, please visit: www.lottebiologics.com 

Innovent Presents at the 43rd Annual J.P. Morgan Healthcare Conference

Advancing into new stage of sustainable growth and global innovation

SAN FRANCISCO and SUZHOU, China, Jan. 17, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, participated in the 43rd Annual J.P. Morgan Healthcare Conference.

During the conference, Dr. De-Chao Michael Yu, Founder, Chairman and CEO of Innovent, delivered a presentation highlighting 2025 as a pivotal year for significantly business growth and concreate steps in global innovation. These efforts will further strengthen the foundation for Innovent’s vision of becoming a global premier biopharma company.

Clear path to sustainable growth


Innovent has established itself as a leading brand in oncology, consistently gaining momentum with an expanding portfolio of synergistic products. Additionally, another key growth driver, the general biomedicine segment, features a highly competitive product lineup, poised to unlock the substantial opportunities in chronic disease areas.

The company remains confident in achieving its domestic product revenue target of 20 billion RMB by 2027. Alongside rapid business growth, Innovent continues to enhance operational efficiency through effective and lean management practices, ensuring sustainable and healthy operating model.

Focus on world-class technology platforms and key therapeutic areas


Innovent Academy, the company’s innovation engine, has built a world-class technology platform, encompassing ScFv engineering, T cell engager (TCE), VHH bispecific antibodies, Topo1i ADC, dual payload ADC, and antibody peptide conjugates (APC). These platforms have consistently delivered innovative molecules, providing a driving force for the company’s long-term development.


In particular, Innovent combines its world-class antibody engineering and multiple sets of differentiated linker payload technologies to create the TOPO1i ADC technology platform (SoloTx) and dual payload ADC technology platform (DuetTx), producing a pipeline of potential best-in-class (BIC) or first-in-class (FIC) ADC candidates.


The company has so far advanced 8 ADC candidates into clinic trials, supported by efficacy and safety data from over 600 patients, with multiple ADCs receiving breakthrough therapy designation (BTD). This further validates the differentiated advantage of the company’s ADC platform technology and its strong clinical execution.


Innovent continues to focus on high-potential therapeutic areas in oncology and general biomedicine. The “PD-1+precision therapies” pipeline strengthens its leadership in oncology, while the “IO+ADC” strategy is set to transform cancer treatment. Meanwhile, its general biomedicine pipeline covers next generation treatments for autoimmune, cardiovascular and metabolic, and ophthalmic diseases, aiming to elevate treatment standards for diverse patient populations.

Embracing new opportunities in global innovation

Innovent Academy’s advancements have paved the way for a globally competitive pipeline of next generation IO and ADC candidates. The company plans to expand into innovative ADCs, bispecific (multi-specific) antibodies, and next-generation autoimmune and CVM therapies for global development.

  • IBI343 (CLDN18.2 ADC): Phase 3 multi-regional clinical trial (MRCT) has been initiated in China and Japan for gastric cancer. Pancreatic cancer MRCT clinical Phase 1 data shows positive efficacy and safety signals in Chinese patients and has started patient enrollment in the U.S. Pivotal clinical trials are anticipated in 2025, subject to PoC validation.
  • IBI363:This first-in-class PD-1/IL-2α-biased bispecific antibody has shown promising Phase 1 clinical data, obtained from hundreds of patients in IO resistant non-small cell lung cancer (NSCLC), melanoma, and IO unresponsive “cold tumor” colorectal cancer (CRC). This points to its potential as the next generation IO cornerstone drug. Innovent is following up on the Phase 1b/2 expansion cohorts of these cancer types. Pivotal clinical studies in IO-resistant advanced squamous NSCLC and IO-naïve advanced melanoma are planned to launch in China in 2025, subject to PoC data and regulatory communication. A Phase 2 clinical study is ongoing in the U.S. and will further expand into cohorts for NSCLC, CRC, and melanoma.
  • IBI3009 (DLL3 ADC): Through global licensing collaboration with Roche, Innovent aims to accelerate the development of this potentially best-in-class DLL3 ADC for small cell lung cancer patients worldwide.


2025 outlook: unlocking growth opportunities

Looking ahead in 2025, the company anticipates a year of rapid growth, driven by six new drug launches and further advancements in commercialization across oncology and general biomedicine. Key highlights include:


  • Mazdutide (GCG/GLP-1): Expected approvals for weight loss and type 2 diabetes indications in the first and second half of 2025, respectively, will provide a best-in-class GCG/GLP-1 dual agonist drug offering robust weight loss and glucose reduction, substantial liver fat reduction as well as comprehensive metabolic benefits for the vast obese, overweight and diabetes population;
  • Teprotumumab (IGF-1R): Anticipated launch as China’s first anti-IGF-1R monoclonal antibody for thyroid eye disease (TED), addressing a 60-year treatment gap.
  • Picankibart (IL-23p19): Approval anticipated by late 2025. Picankibart is the first globally to report that over 80% of subjects achieved PASI 90 (≥90% improvement in psoriasis area and severity index) within 16 weeks of treatment. It also demonstrates clear advantages, including sustained long-term efficacy, effective in patients resistant to IL-17 inhibitors, and flexibility with seasonal dosing intervals. Picankibart is poised to deliver exceptional comprehensive benefits to psoriasis patients in China.

As the company advances key cornerstone products in its pipeline, we are actively expanding the development of mazdutide, teprotumumab, and picankibart into additional indications to maximize the portfolio’s value. Building on this solid foundation, next-generation candidates are gradually entering clinical development, aiming to address global challenges related to aging and chronic disease burden. These innovations focus on extending dosing intervals, oral delivery, and novel mechanisms of action.


Looking ahead to 2025, the company plans to submit NDAs or conduct ongoing registrational trials for seven drugs, while initiating pivotal or registrational trials for seven innovative pipeline candidates, pending PoC results. Additionally, molecules with global potential and novel mechanisms of action (MoAs) will progress into PoC and first-in-human studies. These efforts solidify Innovent’s vision of “growing into a global premier biopharma company.”


Scan the QR code for presentation slides


About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 13 products in the market. It has 4 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

 

Ricoh named a Leader in 2024 IDC MarketScape for Worldwide Cloud Managed Print and Document Services Hardcopy

Company recognised for strengths in portfolio breadth, implementation and delivery, extended services, geographic footprint and global alignment

TOKYO, Jan. 17, 2025 /PRNewswire/ — Ricoh today announced it has been positioned in the Leaders Category of the IDC MarketScape: Worldwide Cloud Managed Print and Document Services Hardcopy 2024 Vendor Assessment (doc #US51572924, November 2024).

A premier global marketing intelligence firm, IDC evaluated vendors who had services and solutions, including cloud-based managed print and document services, contractual print service models that target both enterprise and SMB, and delivery models including capabilities and strategies deployed by hardcopy vendors in support of direct engagements and channel-delivered print services programs.

The IDC MarketScape noted, “Ricoh continues to show leadership in driving workplace innovation across all areas of the print and document ecosystem” and “Ricoh is working across multiple office ecosystems to help customers drive digital transformation by simplifying content-driven processes through the automation of tasks” as being key differentiators contributing to the company’s position as a Leader. Additionally, the IDC MarketScape noted that “Ricoh should be considered by customers looking for globalised service delivery and consistent service quality across various geographies.”

“Ricoh’s position as a Leader in the IDC MarketScape for Cloud Managed Print and Document Services Hardcopy highlights the company’s ability to generate meaningful and innovative workplace services that continue to push the boundaries of what a print and document ecosystem can be,” said Robert Palmer, Research Vice President: Imaging, Printing, and Document Solutions, IDC. “Their strategic approach and comprehensive solutions enable businesses to streamline processes and easily adapt to the ever-evolving needs of modern workplaces.”

The IDC MarketScape identified several strengths exhibited by Ricoh supporting the company as a Leader, with the report noting the following for each:

  • Portfolio Breadth: “Ricoh looks to help customers drive digital transformation through its workflow and collaboration products, while promoting security, productivity, and sustainability.”
  • Implementation and Delivery: “Ricoh’s global sales and professional services organisation plays a pivotal role in identifying customer challenges and delivering tailored business solutions.”
  • Extended Services: “Beyond traditional MPS, Ricoh offers a comprehensive range of services to support clients in their IT needs, including IT services, onsite print services, infrastructure services, cloud and security services, workflow services, and a full range of process automation services.”
  • Geographic Footprint: “Ricoh offers an expanding pool of expertise with extensive global market coverage.”
  • Global Alignment: “Ricoh aligns its cloud services portfolio across all regions, driven by global service needs and a goal to simplify and standardise the go-to-market approach.”

“We believe being recognised as a Leader in Cloud Managed Print and Document Services Hardcopy underscores our commitment to delivering best-in-class workplace services and solutions that empower businesses to optimise workflows and achieve their digital transformation goals for our customers,” said Takahiro Irisa, Senior Corporate Officer and President of Ricoh Digital Services Business Unit, Ricoh Company, Ltd. “We believe this recognition from the IDC MarketScape validates our dedication to innovation, customer-centricity, and driving measurable results for our customers.”

A leading provider of digital workplace services and cloud-based solutions to more than 1.4 million customers worldwide, Ricoh brings technology and people together to solve challenges for organisations seeking to modernise their print infrastructures and accelerate digital transformation.

For more information and to download an excerpt copy of the report, click here (PDF).

-Ends-

About IDC MarketScape

IDC MarketScape vendor assessment model is designed to provide an overview of the competitive fitness of technology and service suppliers in a given market. The research methodology utilises a rigorous scoring methodology based on both qualitative and quantitative criteria that results in a single graphical illustration of each vendor’s position within a given market. IDC MarketScape provides a clear framework in which the product and service offerings, capabilities and strategies, and current and future market success factors of IT and telecommunications vendors can be meaningfully compared. The framework also provides technology buyers with a 360-degree assessment of the strengths and weaknesses of current and prospective vendors.

Related Links

  • IDC MarketScape names Ricoh a Leader in Worldwide Cloud MPS Vendor Assessment

https://www.ricoh.com/info/2022/0208_1   

| About Ricoh |

Ricoh is a leading provider of integrated digital services and print and imaging solutions designed to support the digital transformation of workplaces, workspaces and optimise business performance.

Headquartered in Tokyo, Ricoh’s global operation reaches customers in approximately 200 countries and regions, supported by cultivated knowledge, technologies, and organisational capabilities nurtured over its 85-year history. In the financial year ended March 2024, Ricoh Group had worldwide sales of 2,348 billion yen (approx. 15.5 billion USD).

It is Ricoh’s mission and vision to empower individuals to find ‘Fulfillment through Work’ by understanding and transforming how people work so we can unleash their potential and creativity to realise a sustainable future.

For further information, please visit www.ricoh.com

###

© 2025 RICOH ASIA PACIFIC PTE LTD. All rights reserved. All referenced product names are the trademarks of their respective companies.

Fiji Airways Unveils Massive Sale to Fiji, Australia, New Zealand and Beyond!

NADI, Fiji, Jan. 17, 2025 /PRNewswire/ — Fiji Airways, Fiji’s national airline, has launched incredible flight deals for American travelers looking to escape winter for a relaxing getaway or thrilling adventure.

Until February 7, 2025, Fiji Airways is offering significant savings on round-trip airfares to some of the world’s most sought-after destinations, including the pristine beaches of Fiji, the Great Barrier Reef in Cairns, the iconic landmarks of Sydney, the vibrant streets of Auckland and beyond.

Available on select travel dates, travelers can fly from Los Angeles, San Francisco, Honolulu or Dallas Fort Worth to:

  • Fiji from just USD $748 on a roundtrip Value fare
  • Australia from USD $848 on a roundtrip Value fare
  • New Zealand from USD $848 on a roundtrip Value fare
  • Tonga & Western Samoa from USD $1,298 on a roundtrip Value fare

All economy value fares include one checked bag of up to 30kg, a carry-on bag of up to 7kg, complimentary meals, beverages, and in-flight entertainment, with additional fare options available for those seeking added perks and convenience.

The sale ends February 7, 2025 and is valid for select travel dates across 2025, with limited seats available. Terms and conditions apply.

Travelers can book now on fijiairways.com or through a local travel agent to experience Fiji Airways’ award-winning hospitality from the moment they step on board.

“It’s the perfect time of year to take advantage of discounted airfares and start planning your travels for the year ahead. Whether you’re dreaming of Fiji’s beaches, Australia’s vibrant cities, or New Zealand’s stunning landscapes, these exclusive offers make it easier than ever for Americans to explore exciting destinations around the world,” said Fiji Airways CEO and Managing Director Andre Viljoen.

Fiji Airways flies directly to 26 international destinations from its hub in Nadi, Fiji and offers seamless one-stop connections for Americans to popular cities including but not limited to:

  • Australia: Sydney, Melbourne, Brisbane, Adelaide, Canberra and Cairns from 10th April 2025
  • New Zealand: Auckland, Wellington, Christchurch
  • The South Pacific: Tonga, Western Samoa

About Fiji Airways:

Fiji Airways, Fiji’s national airline, has been named SKYTRAX Best Airline in Australia and the Pacific 2024 for two consecutive years and is ranked 14th in SKYTRAX Global Top 100 Airlines.  The airline was also awarded Best Airline Staff, Best Cabin Crew, Best Economy Class and Best Business Class Onboard Catering in Australia and the Pacific at the 2024 SKYTRAX awards. Fiji Airways has also received the esteemed Five Star Major Airline Award at the 2024 APEX Official Airline Ratings™, an award the airline has been recognised with for three consecutive years.

Founded in 1951, the Fiji Airways airline group comprises Fiji Airways, Fiji’s international airline, and its wholly-owned domestic and regional subsidiary, Fiji Link. From its hubs at Nadi and Suva International Airports, Fiji Airways and Fiji Link serve 108 destinations in over 15 countries (including code-share). Destinations include Fiji, Australia, New Zealand, the US, Canada, the UK, Hong Kong (SAR China), Singapore, India, Japan, China, Samoa, Tonga, Tuvalu, Kiribati, Vanuatu, Solomon Islands and New Caledonia. The Fiji Airways Group brings in 70 percent of all visitors who fly to Fiji, employs over 2000 employees, and earns revenues of over FJD$1.7 billion (USD $770m) in 2023. Fiji Airways rebranded from Air Pacific in June 2013. Visit www.fijiairways.com for more information.

Next Wave of Leading Women in AI Identified in New Global Data Set

Zeki Data’s proprietary data and scoring system has pinpointed the precise women at the forefront of AI innovation. Over 300,000 women across 90+ countries and 250+ sectors of expertise.

LONDON, Jan. 17, 2025 /PRNewswire/ — Zeki Data, a UK-based talent data and analytics company, announced today a new data insights product, Talent Multiplier, capable of identifying the precise women at the forefront of AI innovation organizations desire to hire, fund, or invest in.

Women hold only 25 percent of AI and data roles worldwide and make up less than 30 percent of scientists globally.
Women hold only 25 percent of AI and data roles worldwide and make up less than 30 percent of scientists globally.

Zeki is the only dataset that identifies hidden, underrepresented, and undervalued women science and engineering talent globally. Only 25 percent of AI and data roles worldwide are held by women and Zeki’s proprietary dataset of 300,000+ women in AI is the only dataset of its kind in the world.

“Zeki has answered the question, “where are the women?” with the creation of Talent Multiplier and its Women in AI dataset,” observed Margaux Bergen, Zeki COO and Co-Founder. “All of society benefits when women have equal footing in the development of frontier technologies. Women will shape the next wave of AI and the organizations that actively hire, invest, and fund women AI innovators will lead the market.”

AI will accelerate scientific advancement in every field and according to McKinsey & Company increase corporate profits by potentially $4.4 trillion per year. Intelligence-driven targeting of investments in women can positively impact their level of influence in the development of the next wave of AI built on frontier AI models.

Talent Multiplier provides organizations with a first mover advantage to identify investment opportunities, accelerate innovation, and premier talent. Further Zeki insights on women in AI are available in its free report on Women in AI.

Zeki Data is a talent data and analytics company that applies counter terrorism intelligence techniques to positively identify individuals, organizations, and countries capable of the greatest AI innovation. Learn more at www.zekidata.com.

 

Illuccix® Receives European Approval

MELBOURNE, Australia and LIÈGE, Belgium, Jan. 17, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has received a positive decision on the Marketing Authorization Application (MAA) for its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection), which was submitted in Europe via a decentralized procedure (DCP).

This significant milestone follows the issuance of the Final Assessment Report from the German Competent Authority BfArM[2] as Reference Member State (RMS). Through the DCP, the RMS and all 18 European Economic Area (EEA) Concerned Member States (CMS)[3] agree that Illuccix should receive marketing authorization. The DCP regulatory process will now transition into an administrative national phase to implement authorizations to facilitate commercial launch in each country[4].

Kevin Richardson, Chief Executive Officer, Telix Precision Medicine commented, “We are delighted by this positive outcome, setting the stage for a European commercial launch of Illuccix. This clinically important prostate cancer imaging modality is currently recommended in international clinical practice guidelines including European Association of Urology (EAU) and European Society for Medical Oncology (ESMO).”

PSMA-PET imaging[5] represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT[6] scan) as the standard of care after initial diagnosis and biochemical recurrence (BCR). European guidelines highlight the superior accuracy of PSMA-PET for the staging of primary disease[7] and evaluation of BCR/biochemical persistence (BCP)[8].

About Illuccix® 

Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11   and marketed under the brand name Illuccix®), has been approved by the U.S. Food and Drug Administration (FDA)[9], by the Australian Therapeutic Goods Administration (TGA) [10], and by Health Canada[11].

In Europe, Illuccix, after radiolabelling with gallium-68, will be indicated for detection of PSMA-positive lesions with PET in adults with prostate cancer (PCa) in the following clinical settings:

  • Primary staging of patients with high-risk PCa prior to primary curative therapy
  • Suspected recurrent PCa in patients with increasing levels of serum prostate-specific antigen (PSA) after primary curative therapy
  • Identification of patients with PSMA-positive progressive metastatic castration-resistant prostate cancer (mCRPC) for whom PSMA-targeted therapy is indicated.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on X and LinkedIn.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our registration statement on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals® and Illuccix® names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.

[1] Positron emission tomography.

[2] The German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte).

[3] Germany serves as the Reference Member State in the Decentralised Procedure. The other 18 Concerned Member States are Austria, Belgium, Cyprus, Czech Republic, Denmark, Finland, France, Greece, Ireland, Italy, Luxembourg, Malta, Netherlands, Norway, Portugal, Slovakia, Spain, and Sweden.

[4] Regulatory approval timeframe from EEA CMSs may vary considerably.

[5] Imaging of prostate-specific membrane antigen with positron emission tomography.

[6] Computed tomography.

[7] EAU, ESMO.

[8] EAU.

[9] Telix ASX disclosure 20 December 2021.

[10] Telix ASX disclosure 2 November 2021.

[11] Telix ASX disclosure 14 October 2022.